AI Maverick Intel Announces Letter of Intent to Acquire HEAL Access Canada Inc.

Got story updates? Submit your updates here. ›

AI Maverick Intel, Inc. has entered into a non-binding letter of intent with HEAL Group Holdings Inc. to acquire 100% of the issued and outstanding shares of HEAL Access Canada Inc., a wholly owned subsidiary of HEAL. The proposed transaction will be the first executed under AI Maverick Intel's previously announced right of first refusal agreement with HEAL, which provides the company structured access to evaluate and participate in acquisition opportunities across HEAL's healthcare and technology platform.

Why it matters

The proposed acquisition of HEAL Access Canada represents the initial step in executing AI Maverick Intel's strategy to identify and develop opportunities at the intersection of artificial intelligence, data platforms, and emerging technology-enabled industries. The transaction will provide AI Maverick Intel with an initial operating platform within the broader HEAL ecosystem, establishing a foundation from which the company can evaluate and pursue additional opportunities across the platform.

The details

Under the terms of the letter of intent, AI Maverick Intel would acquire all of the issued and outstanding shares of HEAL Access Canada in consideration of 20 million exchangeable shares of AI Maverick Intel (or a wholly-owned subsidiary) and a secured vendor take-back note in the aggregate principal amount of approximately $5 million. In connection with the proposed transaction, the 120 million common shares of AI Maverick Intel previously agreed to be issued to HEAL pursuant to the ROFR agreement will be adjusted to 100 million common shares.

• The parties have agreed to proceed in good faith toward the negotiation and execution of a definitive agreement on or before May 29, 2026.
• The proposed transaction is expected to close upon the satisfaction of customary conditions, including completion of due diligence, minimum working capital requirements, and receipt of all required regulatory and shareholder approvals.

What they’re saying

What’s next

The parties have agreed to proceed in good faith toward the negotiation and execution of a definitive agreement on or before May 29, 2026. The definitive agreement is expected to reflect customary terms and conditions for a transaction of this nature, including completion of due diligence, minimum working capital requirements, and receipt of all required regulatory and shareholder approvals.